Company intelligence / Profile preview

BIOTEM

Apprieu, Auvergne-Rhone-Alpes, Francebiotem.kr ↗

Ownership: Private
Employees: ~36
Development stage: Commercial

Overview

BIOTEM is an established European CRO/CMO specializing in custom monoclonal/polyclonal/recombinant/humanized/chimeric antibodies and immunoassays. It offers end-to-end solutions from antigen design to large-scale production under ISO-certified quality systems. The company’s Ultimate Humanization® platform enables generation of therapeutic-grade human-like antibodies for preclinical development. No internal pipeline or clinical results as it operates as a fee-for-service partner.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Monoclonal antibodyPolyclonal antibodyRecombinant proteinHumanized antibodyChimeric antibodyFully human antibody
Industry: Contract Research Organization

Partnerships

Privileged partner to ~500 industrial & academic labs worldwide; no major pharma JVs disclosed

Beyond the preview

Go deeper on BIOTEM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIOTEM.

Explore the full profile